Article Text

other Versions

PDF
Original article
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis
  1. Peiwei Li1,2,
  2. Han Wu3,
  3. Honghe Zhang4,
  4. Yu Shi5,
  5. Jinming Xu1,
  6. Yao Ye1,
  7. Dajing Xia1,
  8. Jun Yang5,6,
  9. Jianting Cai2,
  10. Yihua Wu1
  1. 1Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou, China
  2. 2Department of Gastroenterology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
  3. 3The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
  4. 4Department of Pathology, Zhejiang University School of Medicine, Hangzhou, China
  5. 5State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
  6. 6Department of Biomedicine, College of Biotechnology, Zhejiang Agriculture and Forestry University, Hangzhou, China
  1. Correspondence to Dr Yihua Wu, Department of Epidemiology and Health Statistics, Zhejiang University School of Public Health, Hangzhou 310058, China; georgewuer{at}126.com; or Dr Jianting Cai, Department of Gastroenterology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; caijianting111{at}hotmail.com

Abstract

Objective The objective of this meta-analysis was to systematically assess the survival benefit of aspirin use before or after diagnosis for patients with colorectal cancer (CRC).

Design Relevant studies were identified through searching PubMed, Embase and Cochrane databases before May 2014. Two investigators extracted data independently for baseline characteristics and outcomes from the included studies. Either a fixed-effects or a random-effects model was derived to composite the pooled HR for overall mortality and CRC-specific mortality of CRC.

Results Seven studies on postdiagnosis aspirin therapy and seven studies on prediagnosis aspirin use were finally included in this meta-analysis. The overall survival benefit associated with postdiagnosis aspirin use represented an HR of 0.84 (95% CI 0.75 to 0.94). This effect was observed both in colon cancer (HR=0.78, 95% CI 0.64 to 0.96) and in rectal cancer (HR=0.90, 95% CI 0.83 to 0.98). Besides, the survival benefit of postdiagnosis aspirin use appeared to be confined to those patients with positive prostaglandin endoperoxide synthase 2 (PTGS2, also known as cyclooxygenase-2, COX-2) expression (HR=0.65, 95% CI 0.50 to 0.85) and with mutated PIK3CA tumours (HR=0.58, 95% CI 0.37 to 0.90). Aspirin use postdiagnosis was not associated with CRC-specific mortality (HR=0.77, 95% CI 0.52 to 1.14). We observed no evidence of an association between prediagnosis aspirin use and CRC overall mortality (HR=1.01, 95% CI 0.96 to 1.06) or CRC-specific mortality (HR=0.93, 95% CI 0.82 to 1.05).

Conclusions These findings provide further indication that postdiagnosis aspirin therapy improved CRC overall survival, especially for patients with positive PTGS2 (COX-2) expression and mutated PIK3CA tumours.

  • COLORECTAL CANCER

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.